| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $105,563,197 | 19 | 100 |
| Thomas John Charles | EVP, General Counsel | 0 | $0 | 2 | $541,173 | $-541,173 |
| ROMANO KATHRYN | Chief Accounting Officer | 0 | $0 | 2 | $3.6M | $-3.6M |
| ROSSI DINO A | director | 0 | $0 | 2 | $13.18M | $-13.18M |
| JANNEY DANIEL | director | 0 | $0 | 4 | $19.4M | $-19.4M |
| Krishnan Suma | President, R&D | 0 | $0 | 4 | $34.27M | $-34.27M |
| Krishnan Krish S | President and CEO | 0 | $0 | 5 | $34.56M | $-34.56M |
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 …
Over the last 12 months, insiders at Krystal Biotech, Inc. have bought $0 and sold $105.56M worth of Krystal Biotech, Inc. stock.
On average, over the past 5 years, insiders at Krystal Biotech, Inc. have bought $0 and sold $66.29M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $1M was made by Krishnan Suma (Chief Operating Officer) on 2018‑10‑18.
| 2026-09-04 | Sale | Krishnan Krish S | President and CEO | 25,000 0.0851% | $359.32 | $8.98M | -7.43% | |
| 2026-09-04 | Sale | Krishnan Suma | President, R&D | 25,000 0.0851% | $359.32 | $8.98M | -7.43% | |
| 2026-08-14 | Sale | ROSSI DINO A | director | 25,000 0.084% | $329.12 | $8.23M | +0.94% | |
| 2026-06-25 | Sale | Thomas John Charles | EVP, General Counsel | 1,000 0.0033% | $347.27 | $347,270 | -6.37% | |
| 2026-06-04 | Sale | Krishnan Krish S | President and CEO | 960 0.0032% | $301.74 | $289,671 | +9.43% | |
| 2026-06-04 | Sale | Krishnan Krish S | President and CEO | 25,000 0.0849% | $308.12 | $7.7M | +9.43% | |
| 2026-06-04 | Sale | Krishnan Suma | President, R&D | 25,000 0.0849% | $308.11 | $7.7M | +9.43% | |
| 2026-05-26 | Sale | Thomas John Charles | EVP, General Counsel | 642 0.0021% | $302.03 | $193,903 | +11.07% | |
| 2026-03-04 | Sale | Krishnan Krish S | President and CEO | 25,000 0.0849% | $263.17 | $6.58M | +22.03% | |
| 2026-03-04 | Sale | Krishnan Suma | President, R&D | 25,000 0.0849% | $263.21 | $6.58M | +22.03% | |
| 2026-03-02 | Sale | ROMANO KATHRYN | Chief Accounting Officer | 750 0.0025% | $267.60 | $200,700 | +24.68% | |
| 2026-02-27 | Sale | JANNEY DANIEL | director | 11,803 0.0404% | $275.59 | $3.25M | +17.00% | |
| 2026-02-26 | Sale | JANNEY DANIEL | director | 7,741 0.0264% | $275.63 | $2.13M | +16.62% | |
| 2026-02-25 | Sale | JANNEY DANIEL | director | 700 0.0024% | $275.00 | $192,500 | +18.25% | |
| 2026-02-24 | Sale | JANNEY DANIEL | director | 51,720 0.1786% | $267.27 | $13.82M | +20.71% | |
| 2026-02-19 | Sale | ROSSI DINO A | director | 18,950 0.0603% | $261.41 | $4.95M | +22.39% | |
| 2026-02-09 | Sale | ROMANO KATHRYN | Chief Accounting Officer | 12,500 0.043% | $272.14 | $3.4M | +17.48% | |
| 2025-12-04 | Sale | Krishnan Suma | President, R&D | 50,000 0.171% | $220.15 | $11.01M | +36.08% | |
| 2025-12-04 | Sale | Krishnan Krish S | President and CEO | 50,000 0.171% | $220.15 | $11.01M | +36.08% | |
| 2025-07-16 | Sale | Krishnan Suma | President, R&D | 2,918 0.0101% | $150.00 | $437,700 | +67.44% |
| Krishnan Krish S | President and CEO | 1347543 4.5527% | $411.04M | 3 | 39 | +37.28% |
| Krishnan Suma | President, R&D | 1302145 4.3993% | $397.19M | 4 | 38 | +56.29% |
| JANNEY DANIEL | director | 73293 0.2476% | $22.36M | 1 | 12 | +2.09% |
| NORBY R DOUGLAS | director | 9000 0.0304% | $2.75M | 1 | 0 | +106.7% |
| Riley Antony A | Chief Financial Officer | 2800 0.0095% | $854,084.00 | 1 | 0 | +100% |
$159,914,414 | 243 | 18.52% | $8.86B | |
$273,531,368 | 93 | 38.24% | $9.16B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$1,801,511 | 23 | 18.58% | $8.41B | |
$650,670,576 | 22 | 96.65% | $12.6B |
| Increased Positions | 199 | +64.4% | 2M | +7.24% |
| Decreased Positions | 137 | -44.34% | 2M | -6.76% |
| New Positions | 82 | New | 279,886 | New |
| Sold Out Positions | 27 | Sold Out | 168,467 | Sold Out |
| Total Postitions | 371 | +20.06% | 28M | +0.48% |
| Fmr Llc | $1.07M | 14.97% | 4.34M | +6,686 | +0.15% | 2025-09-30 |
| Blackrock, Inc. | $946,685.00 | 13.22% | 3.83M | -11,027 | -0.29% | 2025-09-30 |
| Vanguard Group Inc | $689,424.00 | 9.63% | 2.79M | -30,680 | -1.09% | 2025-09-30 |
| Avoro Capital Advisors Llc | $685,861.00 | 9.58% | 2.78M | +117,777 | +4.43% | 2025-09-30 |
| State Street Corp | $344,678.00 | 4.81% | 1.4M | +40,621 | +3% | 2025-09-30 |
| Soleus Capital Management, L.P. | $251,560.00 | 3.51% | 1.02M | +95,873 | +10.39% | 2025-09-30 |
| Capital World Investors | $199,809.00 | 2.79% | 809,240 | -133,009 | -14.12% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $169,988.00 | 2.37% | 688,460 | 0 | 0% | 2025-09-30 |
| Redmile Group, Llc | $163,303.00 | 2.28% | 661,388 | -2,083 | -0.31% | 2025-09-30 |
| Citadel Advisors Llc | $157,279.00 | 2.2% | 636,988 | +602,428 | +1,743.14% | 2025-09-30 |